NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$15.8b

Last Updated

2021/05/09 22:16 UTC

Data Sources

Company Financials +

Executive Summary

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. More Details


Snowflake Analysis

Outstanding track record and good value.


Similar Companies

Share Price & News

How has PerkinElmer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PKI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PKI's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

8.7%

PKI

-2.2%

US Life Sciences

0.2%

US Market


1 Year Return

52.4%

PKI

51.5%

US Life Sciences

49.9%

US Market

Return vs Industry: PKI exceeded the US Life Sciences industry which returned 51.4% over the past year.

Return vs Market: PKI exceeded the US Market which returned 49.9% over the past year.


Shareholder returns

PKIIndustryMarket
7 Day8.7%-2.2%0.2%
30 Day5.7%-1.0%1.5%
90 Day-2.5%-3.4%3.3%
1 Year52.8%52.4%51.7%51.5%52.4%49.9%
3 Year88.0%86.3%107.4%106.3%63.7%53.4%
5 Year163.5%158.9%216.4%212.6%130.6%104.9%

Long-Term Price Volatility Vs. Market

How volatile is PerkinElmer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PerkinElmer undervalued compared to its fair value and its price relative to the market?

7.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PKI ($140.97) is trading below our estimate of fair value ($152.54)

Significantly Below Fair Value: PKI is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PKI is good value based on its PE Ratio (14.7x) compared to the US Life Sciences industry average (43.6x).

PE vs Market: PKI is good value based on its PE Ratio (14.7x) compared to the US market (20.2x).


Price to Earnings Growth Ratio

PEG Ratio: PKI's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PKI is good value based on its PB Ratio (4x) compared to the US Life Sciences industry average (7.2x).


Future Growth

How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

-26.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PKI's earnings are forecast to decline over the next 3 years (-26.9% per year).

Earnings vs Market: PKI's earnings are forecast to decline over the next 3 years (-26.9% per year).

High Growth Earnings: PKI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PKI's revenue is expected to decline over the next 3 years (-0.9% per year).

High Growth Revenue: PKI's revenue is forecast to decline over the next 3 years (-0.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PKI's Return on Equity is forecast to be low in 3 years time (14.8%).


Past Performance

How has PerkinElmer performed over the past 5 years?

30.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PKI has high quality earnings.

Growing Profit Margin: PKI's current net profit margins (24.2%) are higher than last year (7.8%).


Past Earnings Growth Analysis

Earnings Trend: PKI's earnings have grown significantly by 30.1% per year over the past 5 years.

Accelerating Growth: PKI's earnings growth over the past year (375%) exceeds its 5-year average (30.1% per year).

Earnings vs Industry: PKI earnings growth over the past year (375%) exceeded the Life Sciences industry 17.4%.


Return on Equity

High ROE: PKI's Return on Equity (26.8%) is considered high.


Financial Health

How is PerkinElmer's financial position?


Financial Position Analysis

Short Term Liabilities: PKI's short term assets ($2.7B) exceed its short term liabilities ($1.5B).

Long Term Liabilities: PKI's short term assets ($2.7B) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: PKI's debt to equity ratio (63.4%) is considered high.

Reducing Debt: PKI's debt to equity ratio has increased from 52.8% to 63.4% over the past 5 years.

Debt Coverage: PKI's debt is well covered by operating cash flow (51.4%).

Interest Coverage: PKI's interest payments on its debt are well covered by EBIT (29.3x coverage).


Balance Sheet


Dividend

What is PerkinElmer current dividend yield, its reliability and sustainability?

0.20%

Current Dividend Yield


Upcoming Dividend Payment

TodayMay 10 2021Ex Dividend DateJul 15 2021Dividend Pay DateAug 06 202122 days from Ex DividendBuy in the next 66 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: PKI's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.24%).

High Dividend: PKI's dividend (0.2%) is low compared to the top 25% of dividend payers in the US market (3.4%).


Stability and Growth of Payments

Stable Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: PKI is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PKI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Prahlad Singh (55 yo)

1.42yrs

Tenure

US$9,017,969

Compensation

Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of PerkinElmer, Inc. since December 30, 2019. Dr. Singh serves as the Chairman of the Supervisory Board at EUROIMMUN Medizinische Labordiagnos...


CEO Compensation Analysis

Compensation vs Market: Prahlad's total compensation ($USD9.02M) is about average for companies of similar size in the US market ($USD11.15M).

Compensation vs Earnings: Prahlad's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: PKI's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: PKI's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PerkinElmer, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PerkinElmer, Inc.
  • Ticker: PKI
  • Exchange: NYSE
  • Founded: 1937
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$15.797b
  • Shares outstanding: 112.06m
  • Website: https://www.perkinelmer.com

Number of Employees


Location

  • PerkinElmer, Inc.
  • 940 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings


Biography

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solution...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/09 22:16
End of Day Share Price2021/05/07 00:00
Earnings2021/04/04
Annual Earnings2021/01/03


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.